Three drugs, based on targeting asparagine metabolism in acute lymphoid leukemia and mutant IDH1/2 in acute myeloid leukemia, have received approval from the U.S. Food and Drug Administration (FDA), and many others are under development either in preclinical or clinical studies [201]. This evidence concerns the gene IDH1 and acute myeloid leukemia.